VAX2012Q: Phase Ib/II started

VaxInnate began a double-blind, placebo-controlled Phase Ib/II trial to evaluate single doses of 12, 20, 28 or 36 µg VAX2012Q in up to 200 healthy volunteers ages 65-75. ...